Mosunetuzumab (BTCT-4465A) 是一种全长、完全人源化免疫球蛋白 G1 (IgG1) T 细胞依赖性双特异性 (TDB) 抗体，靶向 CD20 (B 细胞) 和 CD3 (T 细胞)。Mosunetuzumab 重定向 T 细胞以接合和消除恶性 B 细胞，可用于研究复发或难治性 (R/R) B 细胞非霍奇金淋巴瘤 (B-NHL)。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-CD20 & CD3e Reference Antibody (Mosunetuzumab) is 146.05 kDa.

Anti-CD20 & CD3e Reference Antibody (Mosunetuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-CD20 & CD3e Reference Antibody (Mosunetuzumab) is 96.7%, determined by SEC-HPLC.

Mosunetuzumab bound to CD20 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Mosunetuzumab bound to huCD20-VLP , and the EC50 was 0.136 nM.

Mosunetuzumab bound to CD3e protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig 4, Mosunetuzumab bound to huCD3e-Fc , and the EC50 was 0.029 nM.

Mosunetuzumab bound to CD3e protein, and then rebounded to secondary antibodies(Anti-Human-κ+λ-HRP) , and read OD450. As shown in fig 4, Mosunetuzumab bound to huCD3e-Fc , and the EC50 was 0.029 nM.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.